# Antoni Ribas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/antoni-ribas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 165,673 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 160 |
| i10-index | 537 |
| Last Known Institution | APLA Health |
| OpenAlex ID | https://openalex.org/A5083745558 |
| ORCID iD | https://orcid.org/0000-0003-3669-8458 |
| Works | 1,721 |

## Researcher papers

- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Genetic Mechanisms of Immune Evasion in Colorectal Cancer](https://scholariq.org/papers/genetic-mechanisms-of-immune-evasion-in-colorectal-cancer/)
- [PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression](https://scholariq.org/papers/pten-loss-confers-braf-inhibitor-resistance-to-melanoma-cells-through-the/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)
- [High response rate to PD-1 blockade in desmoplastic melanomas](https://scholariq.org/papers/high-response-rate-to-pd-1-blockade-in-desmoplastic-melanomas/)
- [Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence](https://scholariq.org/papers/loss-of-nf1-in-cutaneous-melanoma-is-associated-with-ras-activation-and-mek/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [APLA Health](https://scholariq.org/institutions/apla-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.